Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Jerónimo Rafael Rodríguez-CidJuan José Juárez Vignon-WhaleyGisela Sánchez-DomínguezJordi Guzmán-CastaSonia Carrasco-CaraChardsJorge Guzmán-HuescaRodrigo Riera-SalaCarla Paola Sánchez-RíosMayte Cruz-ZermeñoAlec Seidman-SorsbyIvan de Jesús Rodríguez-ZeaJorge Arturo Alatorre-AlexanderLuis Manuel Martínez-BarreraPatricio Javier Santillán-DohertyAminadab Godina-FloresVictoria Imaz-OlguinRicardo Sosa-SánchezDan Green-RennerPublished in: Journal of cancer research and clinical oncology (2022)
This study demonstrates that platinum therapy alone does not work, and that cisplatin must be the agent of choice and it's used in combination could increase treatment response. The E/C/I regimen demonstrated a in PPS but not for CWS, this is due do their rarity of PPS and that no standard treatment is established yet. The regimen proposed here could represent a possible new standard of treatment for PPS as long as it is validated in a prospective study.